{'fraction_non_alphanumeric': 0.014545454545454545, 'fraction_numerical': 0.0048484848484848485, 'mean_word_length': 5.118518518518519, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The production of inactivated poliovaccine on serially cultivated kidney cells from captive-bred monkeys.

Serially cultivated kidney cells from captive-bred monkeys appear to be very suitable as cell substrate for the production of inactivated poliovaccine. Up to about the 12th generation level no differences in cell growth and virus yield were observed. Also from a safety point of view, application of such cells is preferable to primary cells from wild-caught monkeys, as no evidence was found for the presence of monkey viruses or oncogenic properties in these cells. Application of these cells for the production of inactivated poliovaccine will reduce the number of monkeys needed for this purpose about 50 times and, therefore, could contribute considerably to solve the problem of shortage of monkeys in the world.